Value in Health Regional Issues

Slides:

Advertisements

Similar presentations

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

Advertisements

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

1 Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation R3 Dae Ho Kim / Prof. Jin Bae Kim N Engl J Med 2011; DOI: Manesh R. Patel, M.D.,

Value in Health Regional Issues

Volume 14, Issue 1, Pages (January 2011)

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation Chern-En Chiang, Tsu-Juey.

Making Decisions About Antithrombotic Therapy in Heart Disease

Markov model structure

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma.

Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for.

Volume 17, Issue 2, Pages (March 2014)

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Value in Health Regional Issues

Value in Health Regional Issues

Selecting NOACs for High-Risk Patients

The Essentials for Secondary Stroke Prevention

Value in Health Regional Issues

Efficacy and Safety of Edoxaban in Patients With AF and HF

Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017

Value in Health Regional Issues

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

H-H. Lin, K-L. Hsu, W. W-C. Ko, Y-C. Yang, Y-W. Chang, M-C. Yu, K-T

Atrial Fibrillation.

Value in Health Regional Issues

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Value in Health Regional Issues

Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,

Value in Health Regional Issues

Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.

Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.

Value in Health Regional Issues

Value in Health Regional Issues

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India S.K.R. Sowmya, PharmD, Dixon.

Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan

Value in Health Regional Issues

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Volume 371, Issue 9627, Pages (May 2008)

ACC 2003 Late Breaking Trials

Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Cost-Effectiveness Analysis Expands its Reach Worldwide

Incidence of Intravenous Medication Errors in a Chinese Hospital

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Cost-effectiveness of abdominal aortic aneurysm repair based on aneurysm size Kate C. Young, PhD, Nadia A. Awad, MD, Marcia Johansson, NP, David Gillespie,

Jing Wu, PhD, Ning Yue, MS, Weiwei Xu, PhD

Value in Health Regional Issues

Incidence, outcomes, and effect on quality of life of cranial nerve injury in the Carotid Revascularization Endarterectomy versus Stenting Trial Robert.

R. U. Varier, E. Biltaji, K. J. Smith, M. S. Roberts, M. K. Jensen, J

MATCH Results: Implications for the Internist

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind,

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost- effectiveness analysis Mark D. Schleinitz, MS, MD, J.Peter Weiss, MS,

Brandon J. Patterson, PharmD, PhD, Debora A. Rausch, MD, Debra E

Presentation transcript:

Value in Health Regional Issues Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective Katherine A. Vilain, MPH, Ming Chin Yang, DrPH, Elise Chia Hui Tan, PhD, Kaijun Wang, PhD, Haiyan Li, MS, Wan Hsuan Hsu, MSc, Robert P. Giugliano, David J. Cohen, Elizabeth A. Magnuson, ScD Value in Health Regional Issues Volume 12, Pages 74-83 (May 2017) DOI: 10.1016/j.vhri.2017.03.011 Copyright © 2017 Terms and Conditions

Fig. 1 Representation of the decision model. M represents a Markov process with 20 total health states [9 alive states, each on or off treatment, and 2 absorbing (death) states]. Cycle length is 3 months. Patients remain in their current health state unless a worse event occurs, with the probabilities of these events contingent upon the treatment option and whether patient is currently on or off treatment. Only one event may occur per cycle. The branch from Well represents the potential events, and other health states have branches with similar structures (not shown). CRNM – clinically relevant non-major, EDO – edoxaban, ECH - extracranial hemorrhage, ICH - intracranial hemorrhage, IS - ischemic stroke, MI - myocardial infarction, SEE - systemic embolic event, S/P - status post, TIA - transient ischemic event. Value in Health Regional Issues 2017 12, 74-83DOI: (10.1016/j.vhri.2017.03.011) Copyright © 2017 Terms and Conditions

Fig. 2 Joint distribution of cost and effectiveness differences from probabilistic sensitivity analysis: edoxaban vs. warfarin. Value in Health Regional Issues 2017 12, 74-83DOI: (10.1016/j.vhri.2017.03.011) Copyright © 2017 Terms and Conditions

Fig. 3 Cost-effectiveness acceptability curve, base case results for the comparison of edoxaban to warfarin, from probabilistic sensitivity analysis. Value in Health Regional Issues 2017 12, 74-83DOI: (10.1016/j.vhri.2017.03.011) Copyright © 2017 Terms and Conditions

Fig. 4 1-way sensitivity analysis (tornado diagram) on ICER, edoxaban vs. warfarin. Value in Health Regional Issues 2017 12, 74-83DOI: (10.1016/j.vhri.2017.03.011) Copyright © 2017 Terms and Conditions

Fig. 5 CHADS2 2-3 and CHADS2 4-6 subgroups: Cost-effectiveness acceptability curves from probabilistic sensitivity analyses. Value in Health Regional Issues 2017 12, 74-83DOI: (10.1016/j.vhri.2017.03.011) Copyright © 2017 Terms and Conditions

Fig. 6 VKA-naïve and VKA-experienced strata: Cost-effectiveness acceptability curves from probabilistic sensitivity analyses. Value in Health Regional Issues 2017 12, 74-83DOI: (10.1016/j.vhri.2017.03.011) Copyright © 2017 Terms and Conditions